Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in <i>EGFR</i> -T790M Mutant Lung Cancer
Tadaaki Yamada(Kanazawa University), Seiji Yano(Kanazawa University)
Cited by 97
Related Papers
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
|Nature Communications|2019|360
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer
|Nature Communications|2020|112
High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with <i>EGFR</i>-mutant lung cancer cells
|Oncotarget|2015|58